Cardinal Health, Inc. – Consensus Indicates Potential -1.5% Downside

DirectorsTalk Interviews

Cardinal Health, Inc. with ticker code (CAH) have now 13 analysts covering the stock. The analyst consensus points to a rating of ‘Hold’. The range between the high target price and low target price is between 80 and 56 and has a mean target at 69.54. With the stocks previous close at 70.63 this would indicate that there is a downside of -1.5%. The day 50 moving average is 62.01 while the 200 day moving average is 56.08. The market cap for the company is $19,046m. Visit the company website at: https://www.cardinalhealth.com

The potential market cap would be $18,752m based on the market concensus.

Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.

Share on:

Latest Company News

LAICA targets premium segment with compact filter jug

Compact Italian water jug aims for steady margins through quality design and targeted buyers.

Flooring in 2026 new builds

In 2026, flooring in new builds must balance performance, comfort and design

ACG Metals positioned for strong cash generation and long-term value as copper production ramps up, highlights DIVI fund manager

Gervais Williams, Co-Fund Manager of Diverse Income Trust, explains why ACG Metals’ Turkey-based copper project is generating stronger-than-expected cash flow, how rising commodity prices are supporting valuation, and why the company could deliver long-term shareholder value through growth and future dividends.

Copper positioned for long-term strength as demand outpaces supply

Copper’s long-term outlook remains strong as demand growth from global electrification continues to outpace new supply.

Transitional fuels provide a strategic decarbonisation path for shipping

Quadrise’s marine fuels offer shipping a cost-effective way to cut emissions today while preparing for tomorrow’s clean energy shift.

Dr Tom McColm on Ilika: Stereax revenues and Goliath milestones (LON:IKA)

Clean-tech equities specialist Dr Tom McColm reviews Ilika’s interim results, highlighting stable cash levels, the first recurring commercial revenues from Stereax, and continued technical and manufacturing progress on the Goliath battery platform.

    Search

    Search